Skip to content
Screener

Income Tax at other companies

Eli Lilly logo
Eli LillyLLY
$2.15B+92.8%
Pfizer logo
PfizerPFE
-$407M-389%
Arrowhead Research logo
Arrowhead ResearchARWR
$7K-99.6%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.08M-23.0%
ALN
Alnylam PharmaceuticalsALNY
$13.31M-56.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M0.0%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Gain (loss) on investments, net(10,182)(18,312)12,401(20,476)
Other income, net987102529569
Income (loss) before income tax benefit (expense)(113,382)123,531(205,692)(23,291)
Income tax benefit (expense)(1,264)20(1,482)(96)
Net income (loss)$$(114,646)$123,551$(207,174)(23,387)
Basic net income (loss) per share$$(0.69)$0.78$(1.25)(0.15)
Diluted net income (loss) per share$$(0.69)$0.70$(1.25)(0.15)
Shares used in computing basic net income (loss) per share165,419159,137165,148158,937

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's income tax?
Ionis Pharmaceuticals (IONS) reported income tax of $1.26M in Q2 2026.
How has Ionis Pharmaceuticals's income tax changed year-over-year?
Ionis Pharmaceuticals's income tax increased by 6420.0% year-over-year, from -$20K to $1.26M.
What is the long-term trend for Ionis Pharmaceuticals's income tax?
Over 3 years (2022 to 2025), Ionis Pharmaceuticals's income tax has grown at a -46.6% compound annual growth rate (CAGR), from $11.74M to $1.79M.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Ionis Pharmaceuticals's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude